Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, marking the Zepbound maker's latest push to expand beyond its blockbuster diabetes and weight-loss drugs.

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 receptor agonist Zepbound (tirzepatide) helped more patients achieve improvements in PsA activity and lose a certain percentage of body weight than Taltz alone, the company reported Thursday.

A new definition of obesity could nearly double the prevalence of U.S. adults with the condition, a new study published Monday finds.

Looking to overcome some of the limitations of existing obesity drugs, Alveus Therapeutics has debuted with nearly $160 million in hand and an impressive roster of executives ready to take the biot | Alveus Therapeutics,

Obesity is a complex, chronic condition that affects millions of Americans, and treating it often requires more than just diet and exercise. Hartford HealthCare is taking a more comprehensive, technology-driven approach,

Brian Lian founded publicly traded Viking Therapeutics to focus on metabolic diseases. With obesity drugs in development and the GLP-1 space booming, it’s now a prime M&A target for giants jostling for their share of a potential $100 billion market.

Arrowhead Pharmaceuticals has reported early-phase data on a pair of gene silencing drug candidates in obesity, posting preliminary evidence that the molecules help people shed fat to send its stock up.

New UK regulations restricting junk food advertising aimed at children have come into force, banning online ads for several products and limiting television advertising to post-9 pm slots. The measures are intended to address rising childhood obesity levels.

Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.

Nimbus Therapeutics said on Tuesday it has entered into a multi-year research and licensing agreement with Eli Lilly to develop artificial intelligence-driven new oral treatments for obesity and other metabolic diseases.